(Q28373284)

1

0 references

K M Williamson

2

0 references

J H Patterson

3

0 references

J A Pieper

The Journal of Clinical Pharmacology

5

0 references

language of work or name

English

0 references

publication date

April 1999

0 references

published in

0 references

volume

39

0 references

issue

4

0 references

page(s)

418-24

0 references

cites work

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

High-performance liquid chromatographic method for the determination of fluvastatin in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007886

10.1177/00912709922007886

21 January 2018

Identifiers

DOI

0 references

Fatcat ID

release_5qshor52v5g5pmj53ka45pqh44

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5qshor52v5g5pmj53ka45pqh44